Related Experiment Video

Updated: Apr 25, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
13:53

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes

Published on: December 19, 2020

4.7K

A Licensed Combined Haemophilus influenzae Type b-Serogroups C and Y Meningococcal Conjugate Vaccine

Kirsten P Perrett1, Terry M Nolan, Jodie McVernon

  • 1Vaccine and Immunisation Research Group, Murdoch Childrens Research Institute and Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia, Kirsten.perrett@rch.org.au.

Infectious Diseases and Therapy
|August 20, 2014
PubMed

Insights

A new vaccine, HibMenCY-TT, offers protection against Haemophilus influenzae type b (Hib) and meningococcal serogroups C and Y in infants. Clinical trials show it is safe, well-tolerated, and immunogenic for primary infant vaccination.

Area of Science:

  • Pediatric Infectious Diseases
  • Vaccinology
  • Immunology

Background:

  • Meningococcal disease incidence is highest in infants under one year.
  • Previously, no meningococcal vaccine was licensed for US infants.
  • Serogroups C and Y are significant contributors to invasive meningococcal disease in the US.

Purpose of the Study:

  • To review the novel HibMenCY-TT vaccine.
  • To summarize clinical trial data for HibMenCY-TT.
  • To describe recommended patient populations for HibMenCY-TT vaccination.

Main Methods:

  • Review of a novel vaccine combining Haemophilus influenzae type b (Hib) and serogroups C and Y Neisseria meningitidis conjugated to tetanus toxoid.
  • Summary of Phase II and III clinical trial data.
  • Description of recommended infant vaccination schedules.

Main Results:

  • HibMenCY-TT was found to be well tolerated, safe, and immunogenic in Phase II and III trials.
  • The vaccine was administered at 2, 4, 6, and 12-15 months for primary vaccination.
  • Antibodies against Hib and bactericidal activity against meningococcal serogroups C and Y were induced without increasing injection frequency.

Conclusions:

  • HibMenCY-TT is a novel vaccine for infants providing protection against Hib and meningococcal serogroups C and Y.
  • The vaccine is recommended for infants at increased risk of meningococcal disease.
  • HibMenCY-TT can be administered concomitantly with routine infant vaccines and may benefit global vaccination programs.

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.0K
Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery10:03

Inducing Meningococcal Meningitis Serogroup C in Mice via Intracisternal Delivery

Published on: November 5, 2019

7.0K

Related Concept Videos

Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
9
Viral Meningitis01:18

Viral Meningitis

Viral meningitis is the most common form of meningitis and is often referred to as aseptic meningitis to indicate the absence of bacterial involvement. It is generally milder than bacterial meningitis, with symptoms including fever, headache, stiff neck, drowsiness, nausea, photophobia, and vomiting. Rarely, more severe manifestations or death may occur. Common causative agents include enteroviruses, particularly coxsackie A and B viruses and echoviruses, all members of the Enterovirus genus...
189
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
10
Vaccinations01:51

Vaccinations

Overview
43.8K
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the...
86
Diphtheria01:28

Diphtheria

Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
169